Clinical trial · Interventional
Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma
Phase III Study of Thymopentin in Patients After Curative Resection of Small
NCT00460681CI-TRIAL-00000934unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the clinical efficacy of thymopentin on the prevention of the recurrence and metastasis of small HCC after resection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Thymopentin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- disease-free survival
- timeFrame
- three year
Secondary outcomes (1)
- measure
- overall survival
- timeFrame
- three year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who received curative resection of HBV-related small HCC (pathologically proved, solitary tumour \<5cm, or two/ tumours \<5cm) * Curative resection was defined as (1) the complete resection of all tumor nodules and the cut surface being free of cancer by histological examination; (2) no macroscopic cancerous thrombus was found in the portal vein (main trunk or two major branches), hepatic veins or bile duct, (3) no extrahepatic metastasis was found * Evidence of a positive serum HBV profile but a negative test for anti-HCV antibody * The major organ (heart, liver,lung and kidney) function was normal Exclusion Criteria: * History of cardiac disease * Active clinically serious infection * Known history of human immunodeficiency virus (HIV) infection * Pregnant or breast-feeding patients * Prior use of any systemic anti-cancer treatment for HCC, eg. Chemotherapy, immunotherapy or hormonal therapy (except that hormonal therapy for supportive care is permitted). Antiviral treatment is allowed, however interferon therapy must at least 4 weeks prior randomization * Any condition that is unstable or which could jeopardize the safety of the patient and his / her compliance in the study
References
Publications (0)
Data not yet available
No reference posted for this study.